Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

August 23, 2022 7:30 AM EDT

BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022:

Citi’s 17th Annual Biopharma ConferenceSeptember 7th-8thBoston, MA

Wells Fargo’s 2022 Healthcare ConferenceSeptember 7th-9thBoston, MA

Portfolio managers and analysts who would like to request a meeting with management should contact their representative at the respective hosting firms.

About Sensei BiotherapeuticsSensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:Michael BiegaSenior Director, Investor RelationsSensei Biotherapeutics[email protected]

Media Contact:Chris RaileyTen Bridge Communications[email protected]

Primary Logo

Source: Sensei Biotherapeutics


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Citi, Twitter, Wells Fargo